tracken
Adaptimmune Therapeutics PLC Sponsored ADR Aktie News
Positiv
The Motley Fool
●
etwa ein Jahr alt
GSK gave Adaptimmune nearly $37 million as part of a rights deal. Adaptimmune said it expects to launch its first marketed therapy, possibly as soon as the end of this year.
Negativ
Seeking Alpha
●
etwa ein Jahr alt
ADAP is down after merging with TCRR, while TCRR is up. The merger dilutes ADAP, but in return, it gets one year of additional cash and the TCRR pipeline for free.
Neutral
Pulse2
●
etwa ein Jahr alt
Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. (NASDAQ: TCRR) announced a plan to merge. These are the details.
Negativ
Seeking Alpha
●
mehr als ein Jahr alt
ADAP has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline.
Positiv
The Motley Fool
●
mehr als ein Jahr alt
Positive trial data is powering the biotech's stock higher today.
Neutral
Seeking Alpha
●
mehr als ein Jahr alt
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Dennis Williams - Senior Vice President, Late Stage Development Jo Brewer - Chief Scientific Officer Helen Tayton-Ma...
Neutral
Seeking Alpha
●
fast 2 Jahre alt
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference ...
Positiv
The Motley Fool
●
fast 2 Jahre alt
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
